Pricing Log in Create free account

CorMedix Inc (CRMD) vs Silence Therapeutics PLC Sponsored ADR (SLN)

CorMedix Inc and Silence Therapeutics PLC Sponsored ADR are both Biotechnology companies. CorMedix Inc and Silence Therapeutics PLC Sponsored ADR are of similar size ($581.5M and $581.1M). Silence Therapeutics PLC Sponsored ADR has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 3.0×. CorMedix Inc grew revenue faster over the last twelve months: 280.5% against −97.0%. CorMedix Inc has the higher net margin (40.5% vs 0.00%) and the higher return on invested capital (38.8% vs 0.00%). Across the 18 metrics below, CorMedix Inc leads on 16 and Silence Therapeutics PLC Sponsored ADR on 2.

Valuation

Metric CRMD SLN Biotechnology median
P/E 3.01 n/m 8.50
P/S 1.23 488.70 9.71
P/B 1.24 10.66 2.13
Price to free cash flow 2.27 n/m 20.82
EV/EBITDA 1.81 n/m 0.64
EV/Sales 0.99 402.90 9.21
Earnings yield 33.20% (14.75%) (33.15%)
Free cash flow yield 43.97% (10.32%) (25.50%)

Profitability

Metric CRMD SLN Biotechnology median
Gross margin 82.78% 79.50% 65.16%
Operating margin 46.95% 0.00% 0.00%
Net margin 40.49% 0.00% 0.00%
Free cash flow margin 54.17% 0.00% 0.00%
Return on equity 54.93% (90.41%) (56.36%)
Return on assets 32.36% (44.14%) (48.04%)
Return on invested capital 38.84% 0.00% 0.00%

Growth

Metric CRMD SLN Biotechnology median
Revenue growth (TTM) 280.50% (96.97%) 6.02%
EPS growth (last fiscal year) 780.00% (90.91%) 30.26%
Revenue growth, 5-year CAGR 305.79% (39.74%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRMD SLN Biotechnology median
Debt to equity 0.32 0.00 0.00
Current ratio 2.56 7.42 4.72
Net debt to EBITDA (0.02) 0.94 0.96

Dividend

Metric CRMD SLN Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRMD SLN Biotechnology median
Market cap 581.47m 581.10m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack